Human Acute Myeloid Leukemia Peripheral Blood Mononuclear Cells (Relapsed/Refractory)

Description

Human Acute Myeloid Leukemia Peripheral Blood Mononuclear Cells (Relapsed/Refractory) are derived from the peripheral blood of patients with relapsed/refractory acute myeloid leukemia (AML). They are peripheral blood mononuclear cells primarily composed of leukemic myeloblasts. These cells achieve unlimited proliferation by abnormally activating signaling pathways such as RTK/RAS/MAPK and WNT/β-catenin, and inhibit the expression of myeloid differentiation genes through epigenetic remodeling (such as DNMT3A mutation) to maintain the original state. These cells frequently exhibit complex karyotypic abnormalities, including monosomy 7, trisomy 8, or translocations such as t(8;21). They often express CD33, CD34, and CD117, confirmed via flow cytometry. In addition, they highly express CD47 and secrete immunosuppressive factors such as IL-6/TGF-β, which can inhibit macrophage phagocytosis and induce T cell exhaustion, and cooperate with stromal cells (MSCs) in the bone marrow microenvironment to build an immune escape niche. In translational and preclinical studies, these specimens are widely used to profile gene expression in relapsed AML, investigate disease progression and immune evasion mechanisms, support relapse monitoring, and evaluate novel therapeutic strategies for refractory acute myeloid leukemia.